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a-SynucleinAbstract Neurological disorders (NDs) are one of the leading causes of death especially in the
developed countries. Among those NDs, Alzheimer’s disease (AD) and Parkinson disease (PD)
are heading the table. There have been several reports in the scientiﬁc literatures which suggest
the linkage between cardiovascular disorders (CVDs) and NDs. In the present communication,
we have tried to compile NDs (AD and PD) association with CVDs reported in the literature. Based
on the available scientiﬁc literature, we believe that further comprehensive study needs to be done to
elucidate the molecular linking points associated with the above mentioned disorders.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Alzheimer’s disease (AD) is one of the major neurodegenera-
tive disorders, encountered by more than 35 million people
worldwide in the year 2010 (Prince et al., 2013). It has been
placed 6th leading cause of death in the US only, with an
affected population of 5.4 million in the year 2012
(Alzheimer’s-Association, 2012; Jabir et al., 2014).
Several studies reported occurrence of synaptic loses, prior
to the actual clinical outcome of many neurodegenerative dis-
orders. Scientiﬁc reports had also listed some common set of
molecular pathological events which lead to the synaptic loss
viz. accumulation of certain oligomeric neurotoxic species like
b amyloid (Ab), a-Synuclein and Tau, at different parts of the
brain (Crews and Masliah, 2010; Hilton et al., 2013;
Milnerwood and Raymond, 2010). The pre-ﬁbrillar forms of
the above mentioned proteins especially b amyloid are the
precursor of immunological triggers, oxidative stress and
apoptosis (Stefani and Dobson, 2003). These oligomers can
also interfere with the normal plasticity of the synapse by
interrupting nutrient channels inside the neurons, axonal
transport of synaptic vesicles, impairing mitochondrial func-
tions and triggering glutamate excito-toxicity (Crews and
Masliah, 2010; Crouch et al., 2008). The normal housekeeping
machineries fail to clear the above mentioned oligomeric
peptides in most of the neurodegenerative conditions,
which leads to unbalanced production to clearance ratio
(Deane et al., 2009; Gillis et al., 2013).
Genetic inheritance in case of AD has been suggested via
mutation at three genes present on chromosome 21, chromo-
some 14 and chromosome 1, coding for amyloid precursor
protein (APP), presenilin 1 and presenilin 2 proteins respec-
tively (Alzheimer’s-Association, 2013; Zekanowski et al.,
2003). Certain risk factors like familial history, metabolic syn-
drome, presence of ApoE4 allele, brain trauma, education,
social and cognitive engagement have also been highlighted
in the scientiﬁc literature which promote AD onset at earlier
ages (Alzheimer’s-Association, 2013; Rovelet-Lecrux et al.,
2007).
Recently, number of in vivo and in vitro studies targeted dif-
ferent enzymes and other cellular signaling molecules such as
caspase 2, protein phosphatases, fyn kinase, glycogen synthase
kinase-3b for the alleviations of AD pathology (Braithwaite
et al., 2012; Farr et al., 2014; Jabir et al., 2014; Pozueta
et al., 2013; Schenone et al., 2011).
Parkinson disease (PD) is the second most prevalent age-
related neurodegenerative disorder after AD, with worldwide
occurrence (Khan et al., 2012; Tabrez et al., 2012). Annually,
approx 630,000 people are diagnosed with PD in the US alone.
Moreover, the projected jeopardy associated with this disorder
only from Western Europe is expected to reach 10 million by
2030 (Dorsey et al., 2007; Kowal et al., 2013).It is a chronic disorder caused by the progressive neurode-
generation in the dopaminergic neurons of substantia nigra
resulting in diminished striatal dopamine, which is directly
associated with tyrosine hydroxylase mediated production
(Tabrez et al., 2012). PD is also characterized with several
motor and non-motor deﬁcits along with impaired cognitive,
autonomic as well as psychiatric symptoms (Ferrer et al.,
2012). The well known clinical symptoms of PD include
tremor, muscle rigidity, loss of muscle coordination and
bradykinesia (Tabrez et al., 2012). Secondary manifestation
like dementia, psychiatric issues, visual hallucinations and
depressions may also appear in some cases (Pankratz et al.,
1993; Samii et al., 2004).
Depending upon the clinical onset, PD is categorized as
juvenile onset PD (the clinical symptoms develop within
20 years), early onset PD (developed before 50 years of age)
and late onset PD (developed after the age of 50)
(Bru¨ggemann and Klein, 1993; Lu¨cking et al., 2000; Payami
et al., 2002).
Inclusion bodies ﬁlled with a-Synuclein (an oligomeric pro-
toﬁbril) are known as Lewy bodies (LBs) and their presence is
one of the pathological features of PD (Ferrer et al., 2012;
Lotharius and Brundin, 2002). a-Synuclein has also been
reported to be genetically related with PD onset and also
propagate the disease to the neighboring cells (Stefanis, 2012;
Tabrez et al., 2012).
An earlier study on transgenic mouse expressing human
a-Synuclein suggested the combined role of inclusion bodies
and ubiquitin in the immunological events, which leads to
dopaminergic terminal loss (Masliah et al., 2000). Very
recently, Spinelli et al. (2014) reported over expression of
a-Synuclein protein aggregates at the presynaptic terminals
in the mouse model construct (Spinelli et al., 2014).
It has been suggested in the literature that hereditary
chances of PD occurrence increase 2–3-folds in the immediate
relatives of PD patients (Lesage and Brice, 2009; Warner and
Schapira, 2003). Several genetic mutations have been reported
in different ethnic groups and families of PD patients. How-
ever, only two types of genetic carryover have been depicted
and the genes associated with that have been mapped
(Lesage and Brice, 2009). Autosomal dominant PD have been
reported to possess mutations at LRRK2 (PARK8), SNCA
(PARK1), UCHL1 (PARK5) and LRRK2 (PARK8) genes,
whereas autosomal recessive PD have been reported to have
mutations at PARK2 (PARK2), PARK7 (PARK7) and
PINK1 (PARK6) genes (Klein and Westenberger, 2012;
Lesage and Brice, 2009).
Certain mutation in other genes also increases the risk of
PD development. The individuals afﬂicted with Gaucher’s
disease caused by the mutation in GABA gene coding for
lysosomal housekeeping enzyme beta-glucocerebrosidase, have
higher chances of developing PD (Neumann et al., 2009;
Correlation of neurological disorders with cardiovascular disease 21Shachar et al., 2011). Currently, scientiﬁc community is mainly
focusing toward disturbed intracellular protein equipoise,
mitophagy disturbances and oxidative stress to understand
the pathological and genetical aspects associated with PD
(Khan et al., 2012; Li et al., 2013; Szeto, 2006).
Cardio vascular disease (CVD) is the end result of the
accumulation of atheromatous plaques within the walls of
the coronary arteries and remains the principal cause of death
worldwide (Braunwald, 1997; Murray and Lopez, 1997). The
pathogenic components of atherogenesis have not been
completely elucidated. However, epidemiological studies have
identiﬁed a number of risk factors viz. family history, smoking,
hypertension and elevated serum cholesterol levels associated
with CVD. There is also extensive evidence of the role of
genetic factors in the familial aggregation of CVD and its
predictors (Youseﬁ et al., 2006). Although, there is no doubt
as to the role of genetic background in CVD, external factors
are also known to play a particularly important part. Accord-
ing to present trends in the US, half of healthy 40-year-old
males and one in three healthy 40-year-old women will develop
cardio heart disease in future (Alberti-Fidanza et al., 1994). It
is the leading cause of death of American women, accounting
for 32% of all deaths per year (Berdowska and Zwirska-
Korczala, 2001; Hannonen et al., 1986).
Cardiac failure is often associated with an elderly onset of
PD and its prevalence has been suggested, twice compared
with normal population (Zesiewicz et al., 2004). Though
brain and heart tissues vary a lot in their structure and func-
tion, their unique high energy demand makes them rely on
mitochondrial energy packs (Hemmer and Wallimann, 1993;
Mourier et al., 2014). Despite the highest number of mito-
chondria, both cardiomyocytes and neurons lack mitotic
properties and fail to spot mitochondrial damage (Bhandari
et al., 2014). Recent ﬁndings depicted the association of
mitofusin 2 (Mfn2, a key functional element in heart mito-
phagy) with two other PD associated factors, viz. PINK1
and Parkin (Chen and Dorn, 2013). Any genetic or physio-
logical defects in Parkin-mediated mitophagic signaling,
impair removal of damaged mitochondria and affect both
the brain and heart. Mitochondrial dysfunction and the mis-
handling/perturbed degradation of proteins have both been
implicated in the loss of dopaminergic neurons (Gegg et al.,
2010). There has also been reports that PTEN-inducible
kinase 1 (PINK1)–Parkin mitochondrial quality control
pathway is associated with both PD and heart function.
Another cardinal feature in PD is orthostatic hypotension
(OH), which is referred as consistent fall in both systolic as
well as diastolic blood pressures. Approximately 30–40% of
PD patients exhibit this phenomenon and most of them have
been observed with cardiac nor-adrenergic denervations
(Goldstein, 2006; Jain and Goldstein, 2012).
In a recent study, PD patients reported an increased risk of
ischemic stroke along with other co-morbidities like coronary
heart disease, hypertension, and other heart diseases (Huang
et al., 2013). There have also been reports that PD treatment
by the widely used dopamine agonists pergolide and cabergo-
line causes heart valvulopathy (Massel and Suskin, 2007). The
above mentioned ﬁndings clearly suggest a possible association
between CVD and PD.
Growing evidence also supports a strong association
between cardiovascular disease (CVD), and higher risk ofdementia and AD (Rusanen et al., 2011; Stampfer, 2006).
Several linking features such as hypoxia, amyloid-beta and
oxidative stress had been proposed as a connecting point
between AD and CVD. Both of these diseases could be
considered as vascular disorders because of lack of optimal
blood ﬂow in both the brain and heart. The hypoxic events
in the brain triggers increased amyloid-beta deposition and
plaque formation in central neurons (Sun et al., 2006). More-
over, ischemic lesions could affect speciﬁc neuronal networks
and also trigger inﬂammatory host response, which leads to
the neuronal degeneration (Casserly and Topol, 2004). The
above mentioned hypoxic events could promote the develop-
ment of AD as it results in heart diseases. Certain genetic
factors like Apo E4 carriers are more vulnerable to AD or
dementia compared with CVD (Kivipelto et al., 2008;
Martins et al., 2006). Impaired cognitive functions have been
reported in case of ischemic and atherotic individuals
(Dardiotis et al., 2012). The functional deﬁcits due to atrial
ﬁbrillation, coronary artery disease, aortic or mitral valve
diseases reduce the cerebral blood ﬂow, which leads to
exaggerations in cognitive function arising due to the excess
cerebral accumulation of tau or Ab deposits (Bell and
Zlokovic, 2009; Hakim et al., 2013).
Recently, compiling data from large scale genome wide
association studies on AD pathogenesis, researchers had
concluded the involvement of cardiovascular disease pathway
in AD (Liu et al., 2014). These ﬁndings clearly show a strong
association between AD and CVD.2. Conclusion
Based on our manuscript, it is quite clear that CVD are asso-
ciated with neurological disorders especially AD and PD.
However, a lot of work needs to be done before ﬁnding out
the exact linking point among these diseases.Acknowledgements
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